Progestogen Therapy for Des-Induced Cv Abnormalities

Jones, Lovell Allan

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Cancer Institute (NCI)
• Type: Research Project (R01)
• Project #: 3R01CA044591-02S1
• Application #: 3187264
• Study Section: Experimental Therapeutics Subcommittee 2 (ET)
• Project Start: 1987-09-01
• Project End: 1990-08-31
• Budget Start: 1988-09-01
• Budget End: 1989-08-31
• Support Year: 2
• Fiscal Year: 1989

Institution

• Name: University of Texas MD Anderson Cancer Center
• Type: Hospitals
• DUNS #: 001910777
• City: Houston
• State: TX
• Country: United States
• Zip Code: 77030

Publications

Hajek, R A; King, D W; Hernandez-Valero, M A et al. (2006) Detection of chromosomal aberrations by fluorescence in situ hybridization in cervicovaginal biopsies from women exposed to diethylstilbestrol in utero. Int J Gynecol Cancer 16:318-24

Hajek, R A; Robertson, A D; Johnston, D A et al. (1997) During development, 17alpha-estradiol is a potent estrogen and carcinogen. Environ Health Perspect 105 Suppl 3:577-81

Hajek, R A; Nguyen, T V; Johnston, D A et al. (1993) In vivo induction of increased DNA ploidy of mouse cervicovaginal epithelium by neonatal estrogen treatment. Biol Reprod 49:908-17

Kieback, D G; McCamant, S K; Press, M F et al. (1993) Improved prediction of survival in advanced adenocarcinoma of the ovary by immunocytochemical analysis and the composition adjusted receptor level of the estrogen receptor. Cancer Res 53:5188-92

Scrocchi, L A; Jones, L A (1991) Alteration of proto-oncogene c-fos expression in neonatal estrogenized BALB/c female mice & murine cervicovaginal tumor LJ6195. Endocrinology 129:2251-3